Review Article
Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy
Table 1
Completed clinical trials of combining immunotherapy.
| | ClinicalTrials.gov identifier | Phase | Treatment arms | PFS (month) | ORR (month) |
| | NCT01454102 | I | 4 doses of Niv/Gem/Cis () vs. Niv () vs. Niv/Erlotinib () vs. 4 doses of Ipi/Niv followed by Niv () | 50.5 (18.7 to 75.7) vs.50.6 (27.7 to 69.7) vs.39.7 (26.0 to 53.1) vs.72.4 (54.7 to 84.1) | 41.7 (15.2 to 72.3) vs.23.1 (12.5 to 36.8) vs.19.0 (5.4 to 41.9) vs.47.4 (31.0 to 64.2) | | NCT01927419 | II | 4 doses of Ipi/Niv followed by Niv () vs. 4 doses of Ipi/Pla followed by Pla () | 8.57 (7.03 to NA[1]) vs. 3.73 (2.76 to 5.13) | 59.7 (47.5 to 71.1) vs. 10.8 (3.0 to 25.4) | | NCT02905266 | III | 4 doses of Ipi/Niv followed by Niv () vs. 4 doses of sequential administration of Niv and Ipi Q3W followed by Niv () | 10.25 (2.96 to NA[1]) vs. NA (4.96 to NA) | 52.8 (38.6 to 66.7) vs. 60.4 (46.0 to 73.5) |
|
|
